Iltimo

Iltimo Therapeutics is a Netherlands-based biotechnology company focused on the development of next-generation T-cell receptor (TCR) therapies for solid tumors. Founded as a spin-off from the Netherlands Cancer Institute (NKI), the company utilizes a proprietary platform to identify and validate high-affinity TCRs that target cancer-specific antigens. By engineering patient T cells to express these receptors, Iltimo aims to overcome the challenges of the immunosuppressive tumor microenvironment. The company is led by a team with a proven track record in the cell therapy space, including the founders of Neogene Therapeutics. Iltimo leverages deep expertise in immunology and oncology to advance its pipeline of cell-based immunotherapies.